Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.
You may also be interested in...
SSRI Advisory Committee
FDA "has not yet made a final determination on the need for an advisory board on suicidality in adults" using selective serotonin reuptake inhibitors, Johnson & Johnson says
SSRI Advisory Committee
FDA "has not yet made a final determination on the need for an advisory board on suicidality in adults" using selective serotonin reuptake inhibitors, Johnson & Johnson says
Antidepressant MedGuide Distribution Imminent; Unit-Of-Use Packs To Follow
The new patient Medication Guide is expected to reach pharmacies the week of March 7. The standardized MedGuides will be issued as tear-off pads for about a year until manufacturers implement unit-of-use packaging, which would allow the guide to be pre-packaged with every prescription.